Clinical Trials
11 trialsNCT00128297 2023-03-28
Pamidronate Administration in Breast Cancer Patients With Bone Metastases
Spanish Breast Cancer Research Group
Phase 4 Completed
NCT02721433 2020-12-02
REaCT-BTA
Ottawa Hospital Research Institute
Phase 4 Completed
NCT00004088 2019-07-02
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT00482378 2018-08-14
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
Mayo Clinic
Phase 1/2 Completed
NCT01907880 2017-07-07
ER11-03
Ottawa Hospital Research Institute
Phase 4 Completed
NCT00083382 2015-06-24
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
University of Arkansas
Phase 2 Completed
NCT00033332 2014-04-04
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00004906 2013-05-30
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00124605 2013-01-07
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00083408 2010-07-05
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
University of Arkansas
Phase 2 Completed
NCT00376883 2007-01-04
Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
Nordic Myeloma Study Group
Phase 3 Completed